Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the completion of the transaction, the chief executive officer now directly owns 429,398 shares in the company, valued at $6,771,606.46. This represents a 11.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total value of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04.

Centessa Pharmaceuticals Stock Down 2.4 %

Shares of NASDAQ CNTA opened at $16.28 on Friday. Centessa Pharmaceuticals plc has a 1 year low of $7.38 and a 1 year high of $18.97. The company has a market capitalization of $2.15 billion, a P/E ratio of -10.64 and a beta of 1.53. The company has a 50 day simple moving average of $16.78 and a 200-day simple moving average of $14.80. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. On average, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP lifted its holdings in Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Sandia Investment Management LP acquired a new position in shares of Centessa Pharmaceuticals during the 2nd quarter worth about $90,000. Finally, Fred Alger Management LLC purchased a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Guggenheim upped their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.